BRAF and neoplasm: Our results suggest that only patients with mutant BRAF-V600K/E should be selected for treatment and that patients should be monitored for any secondary tumors that may not carry the BRAF mutation, or for recurrences of tumor cells that have lost the mutant BRAF allele.